Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Faces Budget Crunch In 2023 Under User Fee Legislation

Executive Summary

Provision would prevent FDA from using eventual fee revenue on any building maintenance costs other than leasing and scientific equipment.

You may also be interested in...



User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

House passes bill reauthorizing FDA user fee programs via voice vote and makes many other policy changes, but in the process touts the bill's potential to push drug prices lower.

FDA's White Oak Staff May Move Off-Site To Ease Space Crunch

Facilities in College Park and Laurel, Md. could become new home for some employees now working at headquarters.

US FDA Might Face Funding Penalty For Missing User Fee Goals

Industry representatives support adding a provision to the user fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS121096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel